Xponance Inc. Has $1.40 Million Stock Holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX)

Xponance Inc. reduced its holdings in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX) by 4.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,432 shares of the company’s stock after selling 217 shares during the period. Xponance Inc.’s holdings in Karuna Therapeutics were worth $1,403,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Rhenman & Partners Asset Management AB raised its stake in Karuna Therapeutics by 734.3% during the third quarter. Rhenman & Partners Asset Management AB now owns 292,000 shares of the company’s stock worth $49,374,000 after acquiring an additional 257,000 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Karuna Therapeutics by 2,482.6% during the 4th quarter. SG Americas Securities LLC now owns 174,193 shares of the company’s stock valued at $55,134,000 after purchasing an additional 167,448 shares during the last quarter. Vanguard Group Inc. boosted its position in Karuna Therapeutics by 3.4% in the third quarter. Vanguard Group Inc. now owns 3,203,585 shares of the company’s stock valued at $541,694,000 after buying an additional 105,686 shares in the last quarter. TD Asset Management Inc grew its stake in Karuna Therapeutics by 53.4% during the third quarter. TD Asset Management Inc now owns 227,718 shares of the company’s stock worth $38,505,000 after buying an additional 79,291 shares during the last quarter. Finally, Catalyst Private Wealth LLC increased its holdings in shares of Karuna Therapeutics by 256.5% during the fourth quarter. Catalyst Private Wealth LLC now owns 77,855 shares of the company’s stock worth $24,642,000 after buying an additional 56,018 shares in the last quarter.

Insider Activity at Karuna Therapeutics

In other Karuna Therapeutics news, insider Stephen K. Brannan sold 5,000 shares of Karuna Therapeutics stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $318.34, for a total transaction of $1,591,700.00. Following the transaction, the insider now directly owns 42,604 shares in the company, valued at $13,562,557.36. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 13.20% of the stock is owned by corporate insiders.

Karuna Therapeutics Stock Performance

Karuna Therapeutics stock opened at $329.83 on Thursday. The firm has a market capitalization of $12.58 billion, a P/E ratio of -28.14 and a beta of 1.18. The business has a 50-day moving average of $325.22 and a 200-day moving average of $269.92. Karuna Therapeutics, Inc. has a 1 year low of $158.38 and a 1 year high of $329.99.

Karuna Therapeutics (NASDAQ:KRTX) last issued its earnings results on Thursday, February 22nd. The company reported ($3.01) EPS for the quarter, missing the consensus estimate of ($2.65) by ($0.36). The business’s revenue was down 100.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($2.22) EPS. Research analysts anticipate that Karuna Therapeutics, Inc. will post -11.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

KRTX has been the topic of a number of research analyst reports. Mizuho restated a “neutral” rating and set a $330.00 price target (up from $245.00) on shares of Karuna Therapeutics in a research report on Friday, January 26th. HC Wainwright restated a “neutral” rating and set a $330.00 target price on shares of Karuna Therapeutics in a report on Thursday, March 14th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $330.00 price target (up from $217.00) on shares of Karuna Therapeutics in a report on Thursday, December 28th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $330.00 price objective on shares of Karuna Therapeutics in a report on Tuesday, February 20th. Ten equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Karuna Therapeutics currently has a consensus rating of “Hold” and an average price target of $293.92.

Karuna Therapeutics Profile

Karuna Therapeutics, Inc, a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease.